High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.
about
Natalizumab in Multiple Sclerosis: Long-Term Management.Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
P2860
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.
@ast
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.
@en
type
label
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.
@ast
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.
@en
prefLabel
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.
@ast
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.
@en
P2093
P2860
P1476
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.
@en
P2093
Alessia di Sapio
Francesca Sperli
Manuela Matta
Marco Capobianco
Maria Malentacchi
Marianna Lo Re
Simona Malucchi
P2860
P2888
P304
P356
10.1007/S40120-016-0058-0
P577
2016-12-03T00:00:00Z
P6179
1039029923